Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
Pragyi ShresthaSaritha AdepuRomain R VivèsRana El MasriAstrid KloosterFleur H J KapteinWendy DamStephan J L BakkerHarry van GoorBart van de SluisJacob van den BornPublished in: Journal of the American Society of Nephrology : JASN (2021)
Progressive CKD induces hepatic HS elongation, leading to increased interaction with PCSK9. This might reduce hepatic lipoprotein uptake and thereby induce dyslipidemia in CKD. Therefore, PCSK9/HS may be a novel target to control dyslipidemia.